DEXLEVO - About the company
DEXLEVO is a series B company based in Seoul (South Korea), founded in 2012. It operates as a Developer of biopolymer-based therapeutics for skin disease. DEXLEVO has raised $21.9M in funding. The company has 2550 active competitors, including 871 funded and 626 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.
Company Details
Developer of biopolymer-based therapeutics for skin disease. The product includes Iniblanc is a collagen stimulator that enables regeneration of natural skin collagen in the skin to treat anti-aging. Another product includes DXP01 which is a volumizing filler.
- Website
- dexlevo.co.kr
- Email ID
- *****@dexlevo.com
- Phone Number
- +82 **********
Key Metrics
Founded Year
2012
Location
Seoul, South Korea
Stage
Series B
Total Funding
$21.9M in 2 rounds
Latest Funding Round
Investors
Ranked
1242nd among 2550 active competitors
Similar Companies
Legal entities associated with DEXLEVO
DEXLEVO is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Dexlevo Inc. CIN: 119-86-78150 , South Korea, Active | Oct 14, 2013 | - | - | - |
Sign up to download DEXLEVO's company profile
DEXLEVO's funding and investors
DEXLEVO has raised a total funding of $21.9M over 2 rounds. Its first funding round was on 2018. Its latest funding round was a Series B round on Nov 25, 2021 for $*****. 4 investors participated in its latest round. DEXLEVO has 6 institutional investors.
Here is the list of recent funding rounds of DEXLEVO:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Nov 25, 2021 | 2316312 | Series B | 8191316 | 1482601 | 2953559 | 3477418 |
2018 | 8204 | Series B | 2048 | 3581 | 8589 | 1947 |
Access funding benchmarks and valuations. Sign up today!View details of DEXLEVO's funding rounds and investors
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
DEXLEVO's Competitors and alternates
Top competitors of DEXLEVO include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of DEXLEVO, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 75/100 | |
3rd | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 72/100 | |
4th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
5th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
6th | LEO Pharma 1908, Copenhagen (Denmark), Late Stage | Developer of drugs for treating dermatology diseases | $560M | 71/100 | |
7th | Karyopharm 2008, Newton (United States), Public | Biopharmaceutical company focused on developing and commercializing innovative cancer therapies | $98.4M | 71/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
9th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
10th | Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer | $146M | 71/100 | ||
1242nd |  DEXLEVO 2012, Seoul (South Korea), Series B | Developer of biopolymer-based therapeutics for skin disease | $21.9M | 33/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on DEXLEVO's competitors? Click here to see the top ones
DEXLEVO's Investments and acquisitions
DEXLEVO has made no investments or acquisitions yet.
Reports related to DEXLEVO
Here is the latest report on DEXLEVO's geography:
News related to DEXLEVO
•
•
•
GS Global expands its portfolio with DEXLEVO for the EU and North American marketsBusiness Wire•Jun 23, 2022•GS Global, DEXLEVO, HUGEL & FILS, DEXLEVO
•
•
DEXLEVO surprises the world with the first liquid polymeric fillers in historyBusiness Wire•Feb 11, 2022•DEXLEVO
•
Korea anti-aging polymer maker gets $22mAsian Venture Capital Journal•Dec 07, 2021•DEXLEVO, MAGNA Investment, Smile Gate Investment, DEXLEVO and 3 others
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about DEXLEVO
Explore our recently published companies
- Kela - 2024 founded, Funding Raised company
- BHI - New York City based, 2026 founded, Unfunded company
- Sherwood Crown Investment - Nottingham based, 2024 founded, Unfunded company
- Roman Tiles - London based, 2019 founded, Unfunded company
- Fox59 - 1996 founded, Unfunded company
- Kfor - 1995 founded, Unfunded company
